Press Release | November 23, 2021
Dragonfly Announces Merck Opt-In on Second TriNKET
Read More
News | November 12, 2021
ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
Read More
News | October 20, 2021
imCheck Publishes Comprehensive Overview of the Developmenet Resumts of its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Cells in Science Translational Medicine
Read More
Press Release | October 18, 2021
Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb and Receipt of Milestone Payments Following First Patient Dosing of Two TriNKET™ Immunotherapies
Read More
